Key result
Balloon pulmonary angioplasty emerges as an effective therapy for inoperable CTEPH.
Why the study?
Techniques and strategies for balloon pulmonary angioplasty in inoperable CTEPH patients are not yet unified, and further data are needed to establish BPA as a treatment.
Balloon pulmonary angioplasty is a promising therapeutic option for inoperable CTEPH, though pulmonary endarterectomy remains the gold standard and further data are needed to unify BPA techniques.
In the past 5 years, balloon pulmonary angioplasty (BPA) for patients with chronic thromboembolic pulmonary hypertension (CTEPH) who are deemed inoperable has undergone significant refinement. As a result, the procedure is now used worldwide and has become a promising therapeutic option for those patients. However, pulmonary endarterectomy remains the gold standard treatment for patients with CTEPH because the techniques and strategies for BPA are not yet unified. The best therapeutic option for each patient should be determined based on discussion among a multidisciplinary team of experts. For BPA to become an established treatment for CTEPH, further data are needed. This review summarizes the techniques and strategies of BPA at present and discusses the future development of the procedure.
No takes yet. Share an insight, caveat, or question.
Ogawa et al. (2018) conducted a review in Chronic Thromboembolic Pulmonary Hypertension (CTEPH). Balloon pulmonary angioplasty (BPA) was evaluated. Balloon pulmonary angioplasty has emerged as a promising and effective therapeutic option worldwide for patients with inoperable chronic thromboembolic pulmonary hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: